Rentschler Biopharma SE
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Rentschler Biopharma SE
Russia is planning to register a second COVID-19 vaccine this month, while the UK is ramping up its manufacturing capacity for vaccines and therapeutics.
Frank Mathias, CEO of Rentschler Biopharma, a contract development and manufacturing organization, talks to In Vivo about the company’s new corporate strategy and why he allowed 18 months to prepare that plan for delivery.
The critical time for many drug development companies frequently comes after successful clinical trials, during the regulatory approval process, and beyond. Moreover, the 2018 survey Formulation in the Drug Product Development Process found that formulation issues had led to project failure and significant delays during drug product development.
START-UP’s monthly comprehensive review of emerging life science companies that have received venture funding during the month, including companies within the in vitro diagnostics, pharmaceuticals, research/analytical equipment & supplies, and medical device sectors.
- Contract Manufacturing Organization
- Other Names / Subsidiaries
- Rentschler Biotechnologie GmbH